摘要
目的:观察护肝散治疗脂肪肝的临床效果及安全性。方法:选择脂肪肝患者160例,随机分为两组,治疗组80例口服护肝散,对照组80例口服辛伐他汀,疗程均为3个月。分别于服药前、治疗结束后观察血液有关的生化指标、肝脏B超声像图及临床变化。结果:治疗组和对照组总有效率分别为92.5%和77.5%,两组比较差异有显著性,治疗组的有效率明显高于对照组(P<0.01),治疗组无不良反应发生。结论:护肝散治疗脂肪肝疗效显著,安全性良好。
Objective：To observe the therapeutic effect and safety of Hugan san soft capsule in treating fatty liver. Methods：One hundred and sixty patients with fatty liver were randomly divided into two groups. 80 patients in the treatment group received hugan san and other 80 in the control group received simavastatine treatment for 3 months,and some blood biochemical criterions and the video of liver ultrasound before and after treatment wre observed. Results：The total effective rate in the treatment group was 92.50% ,which was higher than that in the control group（77.50%）,showing significant difference statistieally（P〈0.01）.Conclusion：The hugan san is an effective drug of fatty liver, obviously side effects.
出处
《现代医药卫生》
2006年第11期1608-1610,共3页
Journal of Modern Medicine & Health
关键词
脂肪肝
护肝散
Hugan san sole capsule
Fatty liver
